Immunotherapy with confidence

Subscription Form

About Us

A little more about us

Probiont is a deep-tech company focused on improving personalized cancer care through predictive immunotherapy efficacy assessment.

Our cancer-on-a-chip technology is purposed to emulate the effect of immune checkpoint inhibitor (ICI) cancer drugs, outside of the patient, prior to applying the treatment.

Get The News First

When We Will be Available in The Market
Subscription Form

Problems and Solutions

There is no way to tell which cancer patient will react positively to ICI therapy.​​


01. Reduce Therapy
Globally $40B is spent unnecessarily on immune checkpoint inhibitor (ICI) therapy

02. Cost-Effective Tool
Need for cost-effective, reliable and simple to use tools for predicting ICI efficacy

03. Testing Methods
Pharma industry – growing need for in vitro testing methods for substituting animal tests in ICI drug development​


01. Cost Saving
Costs of cancer care is reduced by up to $300K/year for each patient identified as unsuitable for the treatment
02. Identify Before Treatment
Identifying the right type of treatment before using it​. No wasting of time – getting personalized results within days​
03. Fast Drug Development
Speeding up drug development​ based on personalised testing result



Tripleplex IVD kit is designed to work in a very straight forward and easy to use manner for the end users.

Product Roadmap

Get All Information About The  PROBIONT

Our Team

CEO Founder, entrepreneur, inventor of core technology, worked in drug development, EU regulatory arena, former biotech CTO, bioengineer, PhD in chemistry.​
MD, PhD in Medicine, 15 years experience in cancer therapy and drug development in Academia and Pharma.​​

Contact us

We’d love to hear from you! Send us a message using the form opposite, or email us. We’d love to hear from you! Send us a message using the form opposite, or email us.
Contact Form Demo
Copyright 2023 @ PROBIONT